BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/26/2018 11:38:21 AM | Browse: 763 | Download: 1340
 |
Received |
|
2018-08-07 01:31 |
|
Peer-Review Started |
|
2018-08-07 06:07 |
|
To Make the First Decision |
|
2018-08-27 01:56 |
|
Return for Revision |
|
2018-08-27 06:28 |
|
Revised |
|
2018-09-20 10:59 |
|
Second Decision |
|
2018-09-27 06:18 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-10-05 23:04 |
|
Articles in Press |
|
2018-10-05 23:04 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-10-15 05:26 |
|
Publish the Manuscript Online |
|
2018-10-26 11:38 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Second-line rescue treatment of Helicobacter pylori infection: Where are we now?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Te-Fu Lin and Ping-I Hsu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ping-I Hsu, MD, Attending Doctor, Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, 386 Ta Chung 1st Road, Kaohsiung 813, Taiwan. williamhsup@yahoo.com.tw |
| Key Words |
Helicobacter pylori; Rescue treatment; Levofloxacin-amoxicillin triple therapy; Bismuth quadruple therapy; Tetracycline-levofloxacin quadruple therapy; High-dose dual therapy |
| Core Tip |
The present article reviews current second-line anti-Helicobacter pylori (H. pylori) regimens. Bismuth quadruple therapy and levofloxacin-amoxicillin triple therapy have comparable eradication rates in the rescue treatment of H. pylori infection, while the former has more adverse effects than the latter. High-dose dual therapy has an eradication rate comparable with levofloxacin-amoxicillin triple therapy. Ten-day tetracycline-levofloxacin quadruple therapy achieves a markedly higher eradication rate compared with levofloxacin-amoxicillin triple therapy (98% vs 69%) in patients with failure of standard triple, bismuth quadruple or non-bismuth quadruple therapy. In conclusion, tetracycline-levofloxacin quadruple therapy has the potential to become a universal second-line treatment for H. pylori infection. |
| Publish Date |
2018-10-26 11:38 |
| Citation |
Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i40/4548.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i40.4548 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
